Obsidio Therapeutics is a late preclinical stage company with a lead asset in IND development. OBT-893 is a first in class drug that targets solid tumors in an unprecedented and sustainable way. Unlike standard targeted therapies, OBT-893 is effective against tumors with diverse driver mutations (e.g. Kras, PTEN, P53) and metabolic profiles. This broad activity stems from OBT-893’s ability to simultaneously block both primary and adaptive nutrient sourcing pathways. In multiple animal tumor models OBT-893 has been shown to be broadly effective and cancer selective overcoming the resistance conferred by tumor heterogeneity and limiting the development of acquired resistance.